Video

Platinum Sensitivity and PARP Inhibition in Ovarian Cancer

Related Videos
Jennifer Scalici, MD
Premal Thaker, MD, MS
Kathleen N. Moore, MD, MS
Casey M. Cosgrove, MD, gynecologic oncologist, assistant professor, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute
Casey M. Cosgrove, MD, gynecologic oncologist, assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute
Laura J. Chambers, DO
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Laura J. Chambers, DO
Related Content
Versamune HPV in HPV16-Driven HNSCC ©stock.adobe.com
November 18th 2024

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Gynecologic Oncology
November 14th 2024

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

Kathleen N. Moore, MD, MS
November 12th 2024

Refined Definition of Platinum Resistance, Novel ADCs Could Bring More Changes to Ovarian Cancer Treatment